0000899243-20-025444.txt : 20200916
0000899243-20-025444.hdr.sgml : 20200916
20200916204735
ACCESSION NUMBER: 0000899243-20-025444
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200916
FILED AS OF DATE: 20200916
DATE AS OF CHANGE: 20200916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Logos Global Management LP
CENTRAL INDEX KEY: 0001792126
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 201179928
BUSINESS ADDRESS:
STREET 1: 1 LETTERMAN DRIVE
STREET 2: STE. D3-700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94129
BUSINESS PHONE: 4158014660
MAIL ADDRESS:
STREET 1: 1 LETTERMAN DRIVE
STREET 2: STE. D3-700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-16
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001792126
Logos Global Management LP
1 LETTERMAN DRIVE, SUITE D3-700
SAN FRANCISCO
CA
94129
0
0
1
0
Series B Preferred Stock
Common Stock
804392
I
See footnotes
The Series B Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
The reporting persons are Logos Opportunities Fund II LP (the "Fund"), Logos Global Management LP ("LGM"), Logos Global Management GP LLC ("LGM GP"), Logos Opportunities GP LLC ("Fund GP"), Logos GP LLC ("Logos GP"), Dr. Arsani William and Dr. Graham Walmsley. LGM is the investment adviser of private funds, including the Fund. LGM GP is the general partner of LGM. Fund GP is the general partner of the Fund. Logos GP is the manager of Fund GP. Dr. William and Dr. Walmsley are controlling persons of LGM and Logos GP and managers of the Fund. LGM is filing this report for itself and the other reporting persons. The reporting persons are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.
The Fund holds the securities reported herein directly for the benefit of its investors. The securities may be deemed to be indirectly beneficially owned by LGM as investment adviser to the Fund, by LGM GP as general partner of LGM, by Fund GP as general partner of the Fund, by Logos GP as manager of Fund GP and by Dr. William and Dr. Walmsley as controlling persons of LGM and Logos GP. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
/s/ Arsani William, Managing Partner
2020-09-16